Chief Financial Officer · Lyell Immunopharma, Inc. (LYEL)

Charles Newton

A named executive officer of Lyell Immunopharma in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,317,424

Salary $499,200Stock awards $0Bonus $49,920

FY2022: $3,875,468

1st of 6 named executive officers at Lyell Immunopharma by FY2023 total.

6 named officers on file for Lyell Immunopharma, FY2023

Charles Newton’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • LYEL’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lyell Immunopharma’s whole pay program stands against its peers

  • Lyell Immunopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LYEL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Charles Newton’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Newton compensation by year

Lyell Immunopharma Summary Compensation Table · all 3 fiscal years held
In US dollars, as Lyell Immunopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$426,461$496,172$499,200
Bonus$1,065,096$1,000,000$49,920
Stock awards$0$0$0
Option awards$18,410,845$2,159,500$3,572,687
Non-equity incentive$216,986$212,160$187,200
Pension and deferred compensation$0$0$0
All other$5,404$7,636$8,417
Total$20,124,792$3,875,468$4,317,424

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lyell Immunopharma, Inc. DEF 14A filed April 22, 2024, accession 0001140361-24-021008, and prior-year filings.

How this page was built: the Lyell Immunopharma, Inc. filed document, accession 0001140361-24-021008. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.

$20.1M
$3.9M
$4.3M
FY21
FY22
FY23
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,144,121—$6.24
Option197,662—$6.24
Option274,039—$5.98
Option554,167—$2.13

Per the Outstanding Equity Awards at Fiscal Year-End table in Lyell Immunopharma, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

8 Form 4 lines since the FY2023 proxy (filed April 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-08-21Sale—1,453$10.5415,306
2025-08-20Grant or award—8,000$0.0016,759
2025-08-12Sale—136$10.348,759
2025-08-11Sale—131$10.538,895
2025-03-17Purchase—200,000$0.56200,000
2025-02-10Grant or award—112,500$0.00172,725
2025-02-10Grant or award derivative—450,000$0.00450,000
2025-02-10Grant or award derivative—56,250$0.0056,250

The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Lyell Immunopharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Charles Newton · this pageChief Financial Officer$4,317,424
Matthew LangChief Business Officer$4,008,353
Stephen HillChief Operating Officer$3,108,128
Lynn SeelyPresident, Chief Executive Officer and Director$2,647,476
Tina AlbertsonFormer Chief Medical Officer and Head of Development$2,391,403
Gary LeeChief Scientific Officer$2,226,356

The full Lyell Immunopharma compensation record

free company brief

This page is one person within Lyell Immunopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lyell Immunopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Newton's compensation dossier · One-time report. No refunds.